Skip to main navigation Skip to search Skip to main content

Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta-analysis.

Research output: Contribution to journal › Article

Abstract

INTRODUCTION: The question remains to be elucidated: "Is treatment with antidepressants at doses approved in Japan effective for Japanese patients with MDD?" It is crucial to confirm this in order to provide appropriate treatments for Japanese patients with major depressive disorder (MDD). Therefore, we conducted a systematic review and random-effects pairwise meta-analysis including these nine double-blind, randomized, placebo-controlled trials. METHODS: We calculated the standardized mean difference (SMD) and risk ratio (RR) with a 95% confidence interval (95% CI). RESULTS: Pooled newer antidepressants outperformed placebo regarding improvement of depressive symptom scale scores [SMD (95% CI) = -0.20 (-0.27, -0.12), p 
Original languageEnglish
JournalJapanese Journal of Neuropsychopharmacology
DOIs
Publication statusPublished - 30-08-2023

Fingerprint

Dive into the research topics of 'Newer antidepressant for Japanese adults with major depressive disorder: A systematic review and meta-analysis.'. Together they form a unique fingerprint.

Cite this